Disable motion

XB628:
PD-L1 + NKG2A Bispecific Antibody

XB628 is a first-in-class, bispecific antibody that simultaneously targets PD-L1 and NKG2A and has been shown to be efficacious in tumor cell killing in vitro and in vivo, supporting its further clinical development by Exelixis.

Molecular structure shown is an artistic rendering.

MECHANISM
OF ACTION

Programmed death ligand-1 (PD-L1) is highly expressed on the surface of some tumor cells. PD-L1 binds to the PD-1 receptor on effector T cells infiltrating tumors, inhibiting them from killing tumor cells. Natural killer group 2 member A (NKG2A) is an inhibitory receptor expressed on NK cells and a subset of CD8+ T cells. Binding of NKG2A to its ligand, human leukocyte antigen-E (HLA-E), which is highly expressed on tumor cells, inhibits NK cell–mediated tumor cell killing. Thus, engagement of the PD-L1 and NKG2A immune checkpoint pathways allows tumor cells to evade both adaptive and innate immune surveillance, respectively. XB628 is a bispecific antibody that has two distinct targeted monovalent binding domains, one each for PD-L1 and NKG2A. It has the ability to kill tumor cells by acting as a dual checkpoint inhibitor, with the additional characteristic of recruiting NK cells to tumors.

XB628
CLINICAL TRIAL
INFORMATION

Phase 1 first-in-human dose-escalation study of XB628 in advanced or metastatic solid tumors.

For more information, visit
clinicaltrials.gov/study/NCT06952010

This website includes information on investigational uses of compounds that have not been approved by the U.S. Food and Drug Administration (FDA). Safety and efficacy of investigational compounds and/or investigational uses of approved products have not been established. The information presented should not be construed as a recommendation for use.

Explore All
Pipeline Clinical Trials

XB628:PD-L1 + NKG2A Bispecific Antibody

XB628:
PD-L1 + NKG2A Bispecific Antibody